Brown Advisory’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.25M Sell
6,844
-347
-5% -$63.9K ﹤0.01% 781
2025
Q4
$1.27M Sell
7,191
-22
-0.3% -$3.59K ﹤0.01% 778
2025
Q3
$1.01M Sell
7,213
-18
-0.2% -$2.43K ﹤0.01% 834
2025
Q2
$908K Sell
7,231
-26
-0.4% -$3.24K ﹤0.01% 834
2025
Q1
$993K Sell
7,257
-340,309
-98% -$48.6M ﹤0.01% 790
2024
Q4
$53.1M Buy
347,566
+14,339
+4% +$2.42M 0.07% 197
2024
Q3
$64.6M Sell
333,227
-14,291
-4% -$2.99M 0.08% 179
2024
Q2
$80.6M Buy
347,518
+74,638
+27% +$16.2M 0.11% 147
2024
Q1
$58.8M Buy
272,880
+101,576
+59% +$23.8M 0.08% 186
2023
Q4
$44.3M Buy
171,304
+2,282
+1% +$560K 0.06% 218
2023
Q3
$43.4M Buy
169,022
+4,219
+3% +$1.13M 0.07% 203
2023
Q2
$46.9M Buy
164,803
+3,590
+2% +$1.07M 0.07% 196
2023
Q1
$44.8M Buy
161,213
+11,582
+8% +$3.2M 0.08% 207
2022
Q4
$41.4M Buy
149,631
+24,231
+19% +$6.84M 0.08% 216
2022
Q3
$33.5M Buy
125,400
+9,025
+8% +$1.92M 0.07% 233
2022
Q2
$23.7M Buy
116,375
+7,240
+7% +$1.48M 0.04% 279
2022
Q1
$23M Sell
109,135
-90,191
-45% -$19.6M 0.03% 299
2021
Q4
$47.8M Buy
199,326
+143,819
+259% +$37M 0.06% 226
2021
Q3
$15.7M Buy
55,507
+43,163
+350% +$14.1M 0.02% 329
2021
Q2
$4.28M Buy
12,344
+3,953
+47% +$1.2M 0.01% 482
2021
Q1
$2.35M Buy
8,391
+3,936
+88% +$1.06M ﹤0.01% 574
2020
Q4
$1.09M Sell
4,455
-95
-2% -$24.5K ﹤0.01% 639
2020
Q3
$1.29M Buy
4,550
+124
+3% +$34.6K ﹤0.01% 577
2020
Q2
$1.18M Sell
4,426
-1,010
-19% -$304K ﹤0.01% 563
2020
Q1
$1.72M Sell
5,436
-842
-13% -$256K 0.01% 494
2019
Q4
$1.86M Sell
6,278
-174
-3% -$48.3K ﹤0.01% 530
2019
Q3
$1.5M Sell
6,452
-173
-3% -$40.3K ﹤0.01% 563
2019
Q2
$1.55M Sell
6,625
-1,337
-17% -$309K ﹤0.01% 566
2019
Q1
$1.88M Sell
7,962
-3,997
-33% -$1.26M 0.01% 649
2018
Q4
$3.6M Buy
11,959
+311
+3% +$99.3K 0.01% 472
2018
Q3
$4.12M Sell
11,648
-786
-6% -$271K 0.01% 486
2018
Q2
$3.61M Buy
12,434
+139
+1% +$39.1K 0.01% 513
2018
Q1
$3.37M Buy
12,295
+4,339
+55% +$1.35M 0.01% 453
2017
Q4
$2.53M Buy
7,956
+152
+2% +$48.8K 0.01% 498
2017
Q3
$2.44M Sell
7,804
-4,942
-39% -$1.46M 0.01% 489
2017
Q2
$3.46M Buy
12,746
+5,528
+77% +$1.46M 0.01% 464
2017
Q1
$1.97M Sell
7,218
-437
-6% -$124K 0.01% 518
2016
Q4
$2.17M Sell
7,655
-117
-2% -$34.7K 0.01% 499
2016
Q3
$2.43M Sell
7,772
-4,259
-35% -$1.26M 0.01% 471
2016
Q2
$2.91M Buy
12,031
+4,383
+57% +$1.16M 0.01% 431
2016
Q1
$1.99M Sell
7,648
-2,108
-22% -$557K 0.01% 476
2015
Q4
$2.99M Sell
9,756
-4,071
-29% -$1.17M 0.01% 427
2015
Q3
$4.04M Buy
13,827
+2,425
+21% +$801K 0.01% 387
2015
Q2
$4.61M Buy
11,402
+229
+2% +$91.9K 0.02% 359
2015
Q1
$4.72M Sell
11,173
-1,279
-10% -$504K 0.02% 357
2014
Q4
$4.23M Buy
12,452
+1,469
+13% +$475K 0.01% 368
2014
Q3
$3.63M Buy
10,983
+76
+0.7% +$25.1K 0.01% 376
2014
Q2
$3.44M Sell
10,907
-1,544
-12% -$465K 0.01% 384
2014
Q1
$3.81M Sell
12,451
-1,003
-7% -$318K 0.01% 362
2013
Q4
$3.76M Sell
13,454
-851
-6% -$220K 0.01% 354
2013
Q3
$3.44M Sell
14,305
-92
-0.6% -$20.6K 0.01% 352
2013
Q2
$3.1M Buy
+14,397
New +$3.08M 0.01% 351

Other funds holding BIIB

Brown Advisory's BIIB Position: Q1 2026 in Review

Brown Advisory reduced its Biogen (BIIB) stake by 4.8% in Q1 2026, selling an estimated $63.9K and leaving 6,844 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #781.

Brown Advisory first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $80.6M in Q2 2024. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Brown Advisory held 6,844 shares of Biogen worth $1.25M as of Q1 2026.
  • Brown Advisory sold 347 Biogen shares in Q1 2026, an estimated $63.9K.
  • Biogen made up ﹤0.01% of Brown Advisory's portfolio in Q1 2026, its #781 holding.
  • Brown Advisory first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Brown Advisory's Biogen position peaked at $80.6M in Q2 2024.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.